Long-term outcome of conservative and invasive treatment in patients with hypertrophic obstructive cardiomyopathy

2018 ◽  
Vol 74 (3) ◽  
pp. 253-261 ◽  
Author(s):  
Sarah Hoedemakers ◽  
Bert Vandenberk ◽  
Max Liebregts ◽  
Tijs Bringmans ◽  
Pieter Vriesendorp ◽  
...  
Keyword(s):  
Hypertrophic Obstructive Cardiomyopathy ◽  
Invasive Treatment ◽  
Term Outcome ◽  
Long Term Outcome

Long-term outcome of patients with hepatocellular carcinoma treated with hypofractionated stereotactic radiation therapy as a bridge to liver transplantation.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 368-368
Author(s):  
Alan W. Katz ◽  
Douglas P Rosenzweig
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Complete Response ◽  
Pathological Examination ◽  
Invasive Treatment ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Stereotactic Radiation ◽  
Bridge Therapy

368 Background: Stereotactic hypofractionated radiation therapy (SHORT) is a safe, non-invasive, treatment modality for patients with hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the long-term outcome of patients with HCC receiving SHORT as a bridge therapy to LT. Methods: We reviewed 9 consecutive patients who underwent LT between 2008 and 2010 after receiving SHORT as bridge therapy. Radiation therapy was delivered using a 6 MV linear accelerator and an infrared based patient posititiong system. Total dose was 50 Gy in 10 fractions. Doses were prescribed to the 100% isodose line (IDL), with the 80% IDL covering the gross tumor plus a minimum margin of 7 mm. Survival was measured from the date of LT. Results: Median time from completion of SHORT to LT was 5.9 months (range; 0.9-15.7 months). After a median follow up of 48.6 months (range; 17.8-65.3 months) all patients were still alive. No significant surgical complications were seen in any of the patients. 8 patients demonstrated necrosis in the treated tumors, ranging from 8-100%. Only 1 patient did not show any treatment effect on pathological examination. One patient developed recurrent disease in a lymph node and in the transplanted liver, both treated by SHORT with complete response. Conclusions: SHORT is a safe and effective bridging therapy with patients experiencing excellent disease-free and overall survival following LT.

scholarly journals Long-Term Outcome of Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy

2011 ◽  
Vol 4 (3) ◽  
pp. 256-265 ◽  
Author(s):  
Morten Kvistholm Jensen ◽  
Vibeke Marie Almaas ◽  
Linda Jacobsson ◽  
Peter Riis Hansen ◽  
Ole Havndrup ◽  
...  
Keyword(s):  
Hypertrophic Obstructive Cardiomyopathy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Percutaneous Transluminal

scholarly journals Long-term outcome after percutaneous septal ablation for hypertrophic obstructive cardiomyopathy

2002 ◽  
Vol 39 ◽  
pp. 173 ◽  
Author(s):  
Dirk Welge ◽  
Lothar Faber ◽  
Bernd C. Werlemann ◽  
Leon Krater ◽  
Hubert Seggewiss ◽  
...  
Keyword(s):  
Hypertrophic Obstructive Cardiomyopathy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Percutaneous Septal Ablation

scholarly journals LONG-TERM OUTCOME OF PERCUTANEOUS SEPTAL ABLATION FOR SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY

2010 ◽  
Vol 55 (10) ◽  
pp. A37.E356
Author(s):  
Lothar Faber ◽  
Dirk Welge ◽  
Hubert Seggewiss ◽  
Detlef Hering ◽  
Olaf Oldenburg ◽  
...  
Keyword(s):  
Hypertrophic Obstructive Cardiomyopathy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Percutaneous Septal Ablation
Sign in / Sign up

Export Citation Format

Share Document